natgillin/translations-raw huggingface dataset:
Taking the results of the three main studies together, 34% of the patients taking Vimpat 200 mg a day and 40% of the patients taking Vimpat 400 mg a day with their existing treatment had a reduction in their seizures by at least half. 
Ob upoštevanju rezultatov treh glavnih študij skupaj se je pri 34 % bolnikov, ki so poleg obstoječega zdravljenja jemali zdravilo Vimpat v odmerku 200 mg na dan, in 40 % bolnikov, ki so poleg obstoječega zdravljenja jemali zdravilo Vimpat v odmerku 400 mg na dan, število epileptičnih napadov zmanjšalo vsaj za pol.
For the full list of all side effects and restrictions with Vimpat, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Vimpat glejte navodilo za uporabo.
How is Vimpat used? 
Kako se zdravilo Vimpat uporablja?
The main measure of effectiveness was the number of patients whose number of seizures was at least halved after 12 weeks of treatment with a stable dose. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je število epileptičnih napadov po 12 tednih zdravljenja z ustaljenim odmerkom vsaj prepolovilo.
An additional study in 118 patients was carried out to test that starting treatment with doses of 200 mg Vimpat by infusion, followed by regular doses taken by mouth, can be applied safely and that adequate levels in the body are achieved. 
Dodatna študija je bila izvedena pri 118 bolnikih z namenom proučevanja varnosti začetnega zdravljenja z infundiranjem 200-miligramskega odmerka zdravila Vimpat, ki mu sledijo vzdrževalni odmerki, zaužiti peroralno, in ugotavljanja, ali to privede do ustreznih ravni zdravilne učinkovine v telesu.
Vimpat can only be obtained with a prescription and is available as tablets (50 mg; 100 mg; 150 mg; 200 mg), as a syrup (10 mg/ml) and as a solution for infusion (drip) into a vein. 
Na voljo je v obliki tablet (50 mg, 100 mg, 150 mg, 200 mg), kot sirup (10 mg/ml) in raztopina za infundiranje (kapalna infuzija) v veno.
For more details see the package leaflet. 
Za več informacij glejte navodilo za uporabo.
How does Vimpat work? 
Kako zdravilo Vimpat deluje?
Side effects affecting the nervous system such as dizziness may be higher after a loading dose and dizziness was the most common reason for stopping treatment. 
Neželeni učinki, ki prizadenejo živčni sistem, kot je na primer omotica, utegnejo biti večji po uporabi polnilnega odmerka.
The active substance in Vimpat, lacosamide, is an epilepsy medicine. 
Zdravilna učinkovina v zdravilu Vimpat, lakozamid, je zdravilo proti epilepsiji.
It contains the active substance lacosamide. 
Vsebuje zdravilno učinkovino lakozamid.
Patients were given Vimpat by mouth at a dose of 200 mg, 400 mg or 600 mg a day, or placebo in addition to their existing treatment of up to three other epilepsy medicines. 
Bolniki so poleg obstoječega zdravljenja z največ tremi drugimi zdravili proti epilepsiji začeli peroralno jemati tudi zdravilo Vimpat v odmerku 200 mg, 400 mg ali 600 mg na dan ali placebo.
• Risk Management Plan (RMP) 
- Načrt za obvladovanje tveganja (RMP)
Alternative treatments should be considered. 
Razmisliti je treba o alternativnem zdravljenju.
They are available in packs of: 
Na voljo so v pakiranjih po:
Your doctor will check this. 
To bo preveril vaš zdravnik.
These medicinal products should be used with caution. 
Ta zdravila je treba uporabljati previdno.
Special considerations for patients who smoke 
Posebno opozorilo za bolnike, ki kadijo
Riociguat has a dual mode of action. 
Riociguat ima dvojni mehanizem delovanja.
Your doctor may decide to monitor your blood pressure. 
Zdravnik se lahko odloči, da bo spremljal vaš krvni tlak.
No such effects were observed in adult rats. 
Teh učinkov pri odraslih podganah niso opazili.
The relevance of this finding for humans is unknown. 
Pomen teh izsledkov za ljudi ni znan.
In case of pronounced hypotension, active cardiovascular support may be required. 
V primeru močno izražene hipotenzije je lahko potrebna aktivna kardiovaskularna podpora.
• inoperable CTEPH, 
• neoperabilno CTEPH,
The absolute bioavailability of riociguat is high (94%). 
Absolutna biološka uporabnost riociguata je velika (94 %).
The use of Adempas in children and adolescents (under 18 years of age) should be avoided because efficacy and safety have not been established for this age group. 
Uporabi zdravila Adempas pri otrocih in mladostnikih (starih manj kot 18 let) se je treba izogibati, ker učinkovitost in varnost nista bili dokazani za to starostno skupino.
Until more is known about the implications of these findings the use of riociguat in children and in growing adolescents should be avoided. 
Dokler ni znanega več o pomenu teh izsledkov, se je treba uporabi riociguata pri otrocih in odraščajočih mladostnikih izogibati.
This also includes recreational drugs called poppers. 
To vključuje tudi rekreacijske droge, t. i. »poppers«.
Terminal half-life increased from 7.3 to 9.2 hours and total body clearance decreased from 6.1 to 2.4 L/h. 
Končni razpolovni čas se je povečal s 7,3 na 9,2 ure, celokupni očistek iz telesa pa se je zmanjšal s 6,1 na 2,4 l/h.
Monthly pregnancy tests are recommended. 
Priporoča se mesečna uporaba testov za ugotavljanje nosečnosti.
Tablets can generally be taken with or without food. 
Tablete se lahko jemljejo s hrano ali brez nje.
Frequencies are defined as: very common (≥1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data). 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Elimination half-life is about 7 hours in healthy subjects and about 12 hours in patients. 
Razpolovni čas izločanja je pri zdravih osebah približno 7 ur, pri bolnikih pa 12 ur.
Improved Stable Deteriorated p-value 
izboljšanje stabilno poslabšanje vrednost p
Doses above 1 mg riociguat were not investigated in this study. 
Odmerkov, večjih od 1 mg riociguata, v tej študiji niso preučevali.
Six patients (10%) experienced at least one clinical worsening event, including 2 deaths unrelated to study drug. 
Šest bolnikov (10 %) je imelo vsaj eno klinično poslabšanje, vključno z dvema smrtnima primeroma, ki nista bila povezana z zdravilom v preskušanju.
Your doctor will check if Adempas is suitable for you. 
Vaš zdravnik bo preveril, če je zdravilo Adempas primerno za vas.
The safety and efficacy of riociguat in children and adolescents below 18 years have not been established. 
Varnost in učinkovitost riociguata pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani.
Date of latest renewal: 18 January 2019 
Datum prve odobritve: 27. marec 2014 Datum zadnjega podaljšanja: 18. januar 2019
If you smoke, it is recommended that you stop, as smoking may reduce the effectiveness of these tablets. 
Če kadite, je priporočljivo prenehati s kajenjem, saj lahko kajenje zmanjša učinkovitost teh tablet.
The most serious side effects are: 
Najbolj resni neželeni učinki so:
If your blood pressure drops (which can make you feel dizzy) then you may need immediate medical attention. 
Če se vam krvni tlak naglo zniža (zaradi česar ste lahko omotični), morda potrebujete takojšnjo zdravniško pomoč.
Plasma concentrations of riociguat in smokers are reduced compared to non-smokers. 
Koncentracije riociguata v plazmi so pri kadilcih manjše kot pri nekadilcih.
Adempas can be taken alone or together with certain other medicines used to treat PAH. 
Zdravilo Adempas se lahko jemlje samo ali skupaj z določenimi drugimi zdravili, ki se uporabljajo za zdravljenje PAH.
In case of overdose, standard supportive measures should be adopted as required. 
V primeru prevelikega odmerjanja je treba uvesti ustrezne standardne podporne ukrepe.
65 years or older 
Bolniki, stari 65 let ali več
Patients with mild and moderate renal impairment were included in the pivotal studies. 
Bolniki z blago in zmerno ledvično okvaro so bili vključeni v ključne študije.
Do not stop taking this medicine without talking to your doctor first, because this medicine prevents the progression of the disease. 
Ne prenehajte jemati tega zdravila brez predhodnega posveta z zdravnikom, saj to zdravilo preprečuje napredovanje bolezni.
During the first weeks of treatment your doctor will need to measure your blood pressure at regular intervals. 
V prvih tednih zdravljenja vam bo zdravnik moral meriti krvni tlak v rednih intervalih.
If you are older than 65 years, you have an increased risk of developing low blood pressure. 
Če ste starejši od 65 let, imate povečano tveganje za nizek krvni tlak.
The volume of distribution is moderate with volume of distribution at steady state being approximately 30 L. 
Volumen porazdelitve je zmeren; volumen porazdelitve v stanju dinamičnega ravnovesja je približno 30 l.
Based on this study and as riociguat is not an inducer of any of the relevant metabolic enzymes, also no pharmacokinetic interaction is expected with other hormonal contraceptives. 
Glede na to študijo in ker riociguat ni induktor katerega koli od pomembnih encimov presnove, tudi farmakokinetičnih interakcij z drugimi hormonskimi kontraceptivi ni pričakovati.
If you miss a dose, continue with the next dose as planned. 
Če ste pozabili vzeti odmerek, nadaljujte z naslednjim odmerkom, kot je načrtovano.
Your doctor will regularly monitor you. 
Zdravnik bo redno spremljal zdravljenje.
The European Medicines Agency has deferred the obligation to submit the results of studies with Adempas in one or more subsets of the paediatric population in the treatment of pulmonary hypertension. 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Adempas za eno ali več podskupin pediatrične populacije pri zdravljenju pljučne hipertenzije.
Effects of other substances on riociguat 
Vpliv drugih učinkovin na riociguat
Because the heart must work harder than normal, people with pulmonary hypertension feel tired, dizzy and short of breath. 
Ker mora srce delati močneje kot običajno, se bolniki s pljučno hipertenzijo počutijo utrujene, omotične in zasople.
In case treatment has to be interrupted for 3 days or more, treatment should be restarted with 1 mg three times daily for 2 weeks, and continued with the dose titration regimen as described above. 
Če je treba zdravljenje prekiniti za 3 dni ali več, je treba zdravljenje ponovno začeti z odmerkom 1 mg trikrat na dan 2 tedna, nato pa zdravljenje nadaljevati s titriranjem odmerka, kot je opisano zgoraj.
If your treatment has to be stopped for 3 days or more, please tell your doctor before restarting your treatment. 
Če morate zdravljenje prekiniti za 3 dni ali več, obvestite zdravnika, preden začnete ponovno jemati zdravilo.
Riociguat pharmacokinetics are linear from 0.5 to 2.5 mg. Inter-individual variability (CV) of riociguat exposure (AUC) across all doses is approximately 60%. 
Farmakokinetika riociguata je linearna od 0,5 do 2,5 mg. Interindividualna variabilnost (CV) izpostavljenosti riociguatu (AUC) je za vse odmerke približno 60 %.
With increased doses, over additive effects on systemic blood pressure were observed in some cases. 
Pri povečevanju odmerkov so v nekaterih primerih opazili več kot aditivne učinke na sistemski krvni tlak.
Data from animals indicate that riociguat is excreted into milk. 
Podatki na živalih kažejo, da se riociguat izloča v mleko.
Patients with ALT > 3 x ULN and bilirubin > 2 x ULN were not studied (see section 4.4). 
Bolnikov z ALT > 3 x ULN in bilirubinom > 2 x ULN niso preučevali (glejte poglavje 4.4).
Riociguat is rapidly absorbed with maximum concentrations (Cmax) appearing 1-1.5 hours after tablet intake. 
Riociguat se hitro absorbira in doseže največje koncentracije (Cmax) 1 - 1,5 ure po zaužitju tablete.
In juvenile rats, the changes consisted of thickening of trabecular bone and of hyperostosis and remodeling of metaphyseal and diaphyseal bone, whereas in adolescent rats an overall increase of bone mass was observed. 
Pri mladih podganah so spremembe predstavljali zadebelitev trabekularne kosti in hiperostoza ter preoblikovanje metafiz in diafiz, medtem ko so pri adolescentnih podganah opazili celokupno povečanje kostne mase.
If any of these applies to you, talk to your doctor first and do not take Adempas. 
Če kar koli od navedenega velja za vas, se najprej posvetujte z zdravnikom in ne jemljite zdravila Adempas.
• persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity (see section 5.1). 
• perzistentno ali ponovno CTEPH po kirurškem zdravljenju, za izboljšanje telesne zmogljivosti (glejte poglavje 5.1).
Do not use this medicine after the expiry date which is stated on the blister and carton after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznake "EXP".
Your dose may need to be adjusted. 
Vaš odmerek bo morda treba prilagoditi.
Concomitant use with CYP3A4 inducers 
Sočasna uporaba z induktorji CYP3A4
Individual dose titration at treatment initiation allows adjustment of the dose to the patient´s needs. 
Titriranje odmerka na začetku zdravljenja omogoča prilagoditev le-tega bolnikovim potrebam.
Do not take Adempas during pregnancy. 
Zdravila Adempas ne smete jemati med nosečnostjo.
If this happens, contact your doctor immediately as you may need urgent medical treatment. 
V tem primeru takoj obvestite zdravnika, saj morda potrebujete takojšnjo zdravniško pomoč.
It works by widening the pulmonary arteries (the blood vessels that connect the heart to the lungs), making it easier for the heart to pump blood through the lungs. 
Deluje tako, da razširi pljučne arterije (krvne žile, ki povezujejo srce s pljuči) in zato srce lažje črpa kri skozi pljuča.
Tél : + 33 (0) 1 80 46 40 40 
MSD FRANCE Tél : + 33 (0) 1 80 46 40 40
If there is a chance you could become pregnant, use reliable forms of contraception while you are taking these tablets. 
Če obstaja možnost da zanosite, morate med jemanjem teh tablet uporabljati zanesljive kontracepcijske metode.
The risk of serious and fatal respiratory tract bleeding may be further increased under treatment with riociguat, especially in the presence of risk factors, such as recent episodes of serious haemoptysis including those managed by bronchial arterial embolisation. 
Tveganje za resne in smrtne krvavitve v dihalih se lahko med zdravljenjem z riociguatom še poveča, predvsem ob prisotnosti dejavnikov tveganja, kot so nedavne resne hemoptize, vključno s tistimi po embolizaciji bronhialnih arterij.
Special considerations for patients with kidney or liver problems You should tell your doctor if you have kidney or liver problems. 
Posebna navodila za bolnike, ki imajo težave z ledvicami ali jetri Obvestite zdravnika, če imate težave z ledvicami ali jetri.
Riociguat also directly stimulates sGC independently of NO. 
Riociguat spodbuja sGC tudi neposredno, neodvisno od NO.
Your doctor will monitor your health status and should consider a reduced starting dose for Adempas. 
Zdravnik bo spremljal vaše zdravstveno stanje in razmislil o zmanjšanju začetnega odmerka zdravila Adempas.
95% CI, [p-value] 
95 % CI, [vrednost p]
The tablets should be taken 3 times a day, approximately 6 to 8 hours apart. 
Tablete se jemlje trikrat na dan, približno vsakih 6 do 8 ur.
The safety profile observed in HIV patients taking a single dose of 0.5 mg riociguat together with different combinations of HIV drugs used in HAART was generally comparable to other patient populations. 
Varnostni profil, ki so ga opazili pri bolnikih, okuženih z virusom HIV, ki so jemali enkratni odmerek 0,5 mg riociguata hkrati z različnimi kombinacijami zdravil proti virusu HIV, uporabljenih v HAART, je bil na splošno primerljiv z varnostnim profilom pri drugih populacijah bolnikov.
An open-label extension study (CHEST-2) included 237 patients who had completed CHEST-1. 
V odprto podaljšanje študije (CHEST-2) je bilo vključenih 237 bolnikov, ki so zaključili študijo CHEST-1.
In cigarette smokers riociguat exposure is reduced by 50-60% (see section 5.2). 
Pri kadilcih cigaret se izpostavljenost riociguatu zmanjša za 50 - 60 % (glejte poglavje 5.2).
Inadvertent overdosing with total daily doses of 9 to 25 mg riociguat between 2 to 32 days was reported. 
Poročali so o nenamernih prevelikih dnevnih odmerkih od 9 do 25 mg riociguata med 2. do 32. dnem.
Patients should be aware of how they react to this medicinal product, before driving or using machines. 
Bolniki morajo pred vožnjo ali upravljanjem strojev vedeti, kako se odzivajo na to zdravilo.
Tablets should be taken three times daily approximately 6 to 8 hours apart (see section 5.2). 
Tablete je treba vzeti trikrat na dan, približno vsakih 6 do 8 ur (glejte poglavje 5.2).
In growing, juvenile and adolescent rats, effects on bone formation were seen. 
Pri rastočih, mladih in adolescentnih podganah so opazili učinke na rast in razvoj kosti.
Current smokers should be advised to stop smoking due to a risk of a lower response. 
Kadilcem je treba svetovati, da prenehajo s kajenjem, ker obstaja tveganje za slabši odziv na zdravljenje.
- if you have low blood pressure (systolic blood pressure less than 95 mmHg) before starting first treatment with this medicine. 
- če imate nizek krvni tlak (sistolični krvni tlak manj kot 95 mm Hg) pred začetkom prvega zdravljenja s tem zdravilom).
Blood pressure should be monitored and dose reduction of riociguat be considered. 
Spremljati je treba krvni tlak in razmisliti o zmanjšanju odmerka riociguata.
Adverse reactions were similar to those seen at lower doses (see section 4.8). 
Neželeni učinki so bili podobni tistim, ki so jih opazili pri manjših odmerkih (glejte poglavje 4.8).
What Adempas is and what it is used for 2. 
Kaj je zdravilo Adempas in za kaj ga uporabljamo 2.
Highly active antiretroviral therapy (HAART) 
Visokoaktivno protiretrovirusno zdravljenje (HAART - highly active antiretroviral therapy)
- if you are allergic to riociguat or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na riociguat ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če ste noseči.
What you need to know before you take Adempas 3. 
Kaj morate vedeti, preden boste vzeli zdravilo Adempas 3.
Adempas can be used for patients with CTEPH who cannot be operated on, or after surgery for patients in whom increased blood pressure in the lungs remains or returns. 
Zdravilo Adempas se lahko uporablja pri bolnikih s CTEPH, ki jih ni mogoče operirati, ali pri bolnikih, ki so bili operirani, a je zvišan krvni tlak v pljučih ostal visok ali pa se je ponovno zvišal.
Efficacy in patients with CTEPH 
Učinkovitost pri bolnikih s CTEPH
A careful monitoring of patients taking anticoagulants according to common medical practice is recommended. 
Pri bolnikih, ki jemljejo antikoagulante, se priporoča skrbno spremljanje v skladu z običajno klinično prakso.
In addition, ritonavir showed inhibition of P-gp. 
Poleg tega je ritonavir zaviral P-gp.
If you are 65 years or older your doctor will take extra care in adjusting your dose of Adempas, because you may be at greater risk of low blood pressure. 
Če ste stari 65 let ali več, vam bo zdravnik posebno previdno določil odmerek zdravila Adempas, saj pri vas obstaja večje tveganje za nizek krvni tlak.
The safety of Adempas has been evaluated in phase III studies of 681 patients with CTEPH and PAH receiving at least one dose of riociguat (see section 5.1). 
Varnost zdravila Adempas so ocenjevali v študijah faze III, v katere je bilo vključenih 681 bolnikov s CTEPH in PAH, ki so prejeli vsaj en odmerek riociguata (glejte poglavje 5.1).
NAME OF THE MARKETING AUTHORISATION HOLDER Bayer (Logo) 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Bayer (logotip)
Developmental toxicity studies in rats and rabbits have shown reproductive toxicity of riociguat. 
Študije razvojne toksičnosti pri podganah in kuncih so pokazale toksičnost riociguata na sposobnost razmnoževanja.
Intra-cellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis, and inflammation. 
Znotrajcelični cGMP ima pomembno vlogo pri uravnavanju žilnega tonusa, proliferacije, fibroze in vnetja.
Dizziness has been reported and may affect the ability to drive and use machines (see section 4.8). 
Poročali so o omotici, ki lahko vpliva na sposobnost vožnje in upravljanja s stroji (glejte poglavje 4.8).
Results were consistent in the main sub-groups evaluated (ITT analysis, see table 2). 
Izsledki so bili skladni v vseh glavnih ovrednotenih podskupinah (analiza glede na namero zdravljenja (ITT - intention-to-treat, glejte preglednico 2).
It may cause side effects such as dizziness. 
Zdravilo lahko povzroči neželene učinke, kot je omotičnost.
These findings were in accordance with improvements in additional haemodynamic parameters. 
Ti izsledki so bili v skladu z izboljšanji drugih hemodinamskih parametrov.
Hospitalisations due to PH Decrease in 6MWD due to PH Persistent worsening of Functional Class due to PH 
bolniki s kakršnim koli kliničnim poslabšanjem smrt hospitalizacija zaradi PH skrajšanje 6MWD zaradi PH vztrajno poslabševanje funkcijskega razreda zaradi PH uvedba novega zdravljenja PH
Bayer (logo) 
Bayer (logotip)
The use of riociguat in other forms of PAH not studied is not recommended (see section 5.1). 
Uporabe riociguata se ne priporoča pri drugih, neraziskanih oblikah PAH (glejte poglavje 5.1).
Treatment should only be started and monitored by a doctor experienced in the treatment of CTEPH or PAH. 
Zdravljenje mora uvesti in nadzirati zdravnik, ki ima izkušnje z zdravljenjem CTEPH ali PAH.
Your doctor will decide with you if you either should stop breast-feeding or stop treatment with Adempas. 
Zdravnik se bo skupaj z vami odločil, ali boste prenehali dojiti ali pa se boste prenehali zdraviti z zdravilom Adempas.
All patients were WHO Functional Class III and 82% received background therapy with an endothelin receptor antagonist (ERA). 
Vsi bolniki so spadali v III. funkcijski razred po klasifikaciji SZO in 82 % jih je prejemalo osnovno zdravljenje z antagonisti endotelinskih receptorjev (ERA - endothelin receptor antagonist).
If you have taken more tablets than you should and experience any side effects (see section 4), please contact your doctor. 
Če ste vzeli večji odmerek zdravila Adempas, kot bi smeli Če ste vzeli več tablet, kot bi smeli, in imate kakršne koli neželene učinke (glejte poglavje 4), se posvetujte z zdravnikom.
Riociguat has vasodilatory properties which may result in lowering of blood pressure. 
Riociguat deluje vazodilatacijsko, kar ima lahko za posledico znižanje krvnega tlaka.
Please tell your doctor if you smoke or if you stop smoking during treatment. 
Zdravnika obvestite, če kadite ali če med zdravljenjem prenehate kaditi.
You will receive Adempas only for special types of pulmonary arterial hypertension (PAH), see section 1. 
Zdravilo Adempas boste prejeli le za določeno obliko pljučne arterijske hipertenzije (PAH), glejte poglavje 1.
An open-label extension study (PATENT-2) included 396 patients who had completed PATENT-1 at the cut-off-date. 
V odprto podaljšanje študije (PATENT-2) je bilo vključenih 396 bolnikov, ki so zaključili študijo PATENT-1 na presečni dan zbiranja podatkov.
Due to the potential for serious adverse reactions in breast-fed infants Adempas should not be used during breast-feeding. 
Zaradi možnih resnih neželenih učinkov pri dojenčkih, se zdravila Adempas ne sme uporabljati med dojenjem.
you have any symptoms of low blood pressure (hypotension) such as dizziness, lightheadedness, or fainting or if you are taking medicines to lower your blood pressure or medicines that cause an increase in urination or if you have problems with your heart or circulation. 
- če imate simptome nizkega krvnega tlaka (hipotenzija), kot so omotica, vrtoglavica ali omedlevica, ali če jemljete zdravila za zniževanje krvnega tlaka ali zdravila, ki povečajo pogostnost uriniranja, ali če imate težave s srcem ali krvnim obtokom.